FY2022 EPS Estimates for MiMedx Group, Inc. (NASDAQ:MDXG) Decreased by Zacks Small Cap

MiMedx Group, Inc. (NASDAQ:MDXGGet Rating) – Analysts at Zacks Small Cap decreased their FY2022 earnings per share (EPS) estimates for MiMedx Group in a research note issued on Monday, September 12th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will earn ($0.14) per share for the year, down from their prior estimate of ($0.13). The consensus estimate for MiMedx Group’s current full-year earnings is ($0.29) per share.

Several other equities analysts also recently issued reports on MDXG. StockNews.com downgraded MiMedx Group from a “buy” rating to a “hold” rating in a research report on Friday, September 9th. HC Wainwright cut their target price on MiMedx Group from $8.50 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, September 7th.

MiMedx Group Stock Performance

Shares of MDXG stock opened at $3.46 on Wednesday. The business’s fifty day simple moving average is $3.68 and its 200-day simple moving average is $3.98. The company has a market cap of $393.09 million, a PE ratio of -13.84 and a beta of 1.75. The company has a current ratio of 3.53, a quick ratio of 3.17 and a debt-to-equity ratio of 586.91. MiMedx Group has a 12-month low of $3.04 and a 12-month high of $8.69.

MiMedx Group (NASDAQ:MDXGGet Rating) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). The firm had revenue of $66.88 million during the quarter, compared to analyst estimates of $65.07 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Silvercrest Asset Management Group LLC lifted its stake in MiMedx Group by 13.7% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 217,696 shares of the company’s stock valued at $1,315,000 after buying an additional 26,236 shares in the last quarter. apricus wealth LLC purchased a new position in MiMedx Group in the 4th quarter worth approximately $2,666,000. Citigroup Inc. lifted its stake in MiMedx Group by 197.7% in the 4th quarter. Citigroup Inc. now owns 189,101 shares of the company’s stock worth $1,142,000 after purchasing an additional 125,572 shares in the last quarter. Disciplined Growth Investors Inc. MN lifted its stake in MiMedx Group by 3.7% in the 1st quarter. Disciplined Growth Investors Inc. MN now owns 330,380 shares of the company’s stock worth $1,556,000 after purchasing an additional 11,648 shares in the last quarter. Finally, Isthmus Partners LLC lifted its stake in MiMedx Group by 18.9% in the 1st quarter. Isthmus Partners LLC now owns 255,872 shares of the company’s stock worth $1,205,000 after purchasing an additional 40,681 shares in the last quarter. 60.86% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other MiMedx Group news, insider Robert Benjamin Stein sold 19,500 shares of the stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $3.62, for a total transaction of $70,590.00. Following the sale, the insider now directly owns 314,505 shares of the company’s stock, valued at approximately $1,138,508.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Robert Benjamin Stein sold 19,500 shares of the stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $3.62, for a total transaction of $70,590.00. Following the sale, the insider now directly owns 314,505 shares of the company’s stock, valued at approximately $1,138,508.10. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Rohit Kashyap sold 12,343 shares of the stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $4.21, for a total transaction of $51,964.03. Following the sale, the insider now directly owns 430,072 shares in the company, valued at $1,810,603.12. The disclosure for this sale can be found here. In the last three months, insiders have sold 73,946 shares of company stock valued at $272,928. Company insiders own 19.60% of the company’s stock.

About MiMedx Group

(Get Rating)

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.

Recommended Stories

Earnings History and Estimates for MiMedx Group (NASDAQ:MDXG)

Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.